What is Ultromics?
Founded as a spin-out from the University of Oxford, Ultromics is fundamentally redefining the standard of care in cardiology. The company specializes in AI-powered diagnostic software that integrates seamlessly with existing ultrasound infrastructure to detect complex heart diseases with unprecedented accuracy. By partnering with prestigious institutions such as the Mayo Clinic and the NHS, Ultromics has developed a robust clinical evidence base for its EchoGo platform. The technology serves as a critical decision-support tool, enabling clinicians to identify pathologies that might otherwise remain undetected during standard echocardiographic examinations, thereby improving patient outcomes and reducing the burden on healthcare providers.
How much funding has Ultromics raised?
Ultromics has raised a total of $100.8M across 4 funding rounds:
Angel/Seed
$2.8M
Series A
$10M
Series B
$33M
Series C
$55M
Angel/Seed (2017): $2.8M with participation from Oxford Sciences Enterprises
Series A (2018): $10M, investors not publicly disclosed
Series B (2021): $33M supported by GV, Optum Ventures, and The Blue Venture Fund
Series C (2025): $55M featuring Oxford University, The University of Chicago, Google, Allegis Capital, Blue Ventures, Lightrock, and Oxford Sciences Enterprises
Key Investors in Ultromics
Oxford Sciences Enterprises
An independent investment firm that partners with the University of Oxford to build and scale transformational businesses derived from world-class research.
GV
A prominent venture capital firm that invests across multiple stages and sectors, with a specific focus on life sciences and frontier technology innovations.
Optum Ventures
The venture capital arm of Optum, dedicated to investing in early-stage companies that aim to disrupt the healthcare status quo and improve patient outcomes.
What's next for Ultromics?
With this latest round of financing, Ultromics is well-positioned to expand its footprint in the U.S. and international markets. The strategic focus will likely shift toward deepening the integration of its AI algorithms into routine clinical practice and expanding the diagnostic capabilities of the EchoGo platform to cover a broader spectrum of cardiovascular conditions. As the company matures, it is expected to leverage its strong institutional partnerships to drive adoption among large-scale health systems, ultimately aiming to establish its diagnostic suite as an essential component of the modern digital health ecosystem.
See full Ultromics company page
